Core Insights - In the first half of 2025, China's pharmaceutical import and export trade remained stable despite a complex external environment, with a total trade volume of $97.95 billion, a slight increase of 0.2% year-on-year [1] - Exports amounted to $54.54 billion, reflecting a year-on-year growth of 3.8%, while imports totaled $43.41 billion, showing a decline of 3.9% [1] Pharmaceutical Products Overview - The export of key pharmaceutical products such as raw materials, hospital diagnostics and treatments, disposable consumables, and Western medicine formulations continued to grow, with the main export markets, excluding the U.S., also seeing increases [1] - The decline in imports was primarily attributed to a significant drop in medical device imports across the board [1] Traditional Chinese Medicine (TCM) - The import and export volume of TCM products was $3.97 billion, down 4.6% year-on-year, with exports at $2.54 billion (down 4.3%) and imports at $1.43 billion (down 5.2%) [2] - Notable declines in export volumes were observed for key TCM products, with prices for TCM products decreasing by 23% year-on-year [2] - TCM imports showed a positive trend with a 14.9% increase, supported by favorable policies and the addition of 24 new importable TCM materials [2] Western Medicine - The import and export volume of Western medicine products remained stable, with exports at $27.93 billion (up 3.7%) and imports at $24.99 billion (down 3.9%) [3] - Raw material exports reached $27.93 billion, with a slight price decrease of 1.8%, while vitamin exports saw significant growth [3] - The export of Western medicine formulations grew by 6.5%, with notable increases in hormone and vitamin products [4] Medical Devices - Medical device exports totaled $24.1 billion, reflecting a 5% increase, while imports were $16.99 billion, down 3.9% [5] - Significant growth was noted in hospital diagnostics and treatment categories, with specific devices like artificial joints and non-invasive ventilators showing substantial increases [5][6] - However, the overall import of medical devices saw a decline, with notable drops in various categories including in vitro diagnostic reagents and X-ray equipment [6] Trade Partners and Market Dynamics - China's pharmaceutical trade involved over 190 countries, with the EU, the U.S., and ASEAN being the top three partners, accounting for 60.5% of total trade [7] - Trade with the EU and the U.S. saw declines, while trade with ASEAN and Belt and Road Initiative countries experienced growth [7][9] - The export to Belt and Road countries reached $20.77 billion, up 4.5%, indicating a growing acceptance and demand for Chinese pharmaceutical products in these markets [9] Emerging Markets - Exports to BRICS countries like Russia and Brazil showed significant growth, while imports from Latin America also increased [9] - The stability of traditional products combined with the exploration of emerging markets is becoming essential for the international development of the industry [9]

数据来源：中国海关，智研咨询整理 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 数据来源：中国海关，智研咨询整理 相关报告：智研咨询发布的《2025-2031年中国医药行业市场全景调研及发展趋向研判报告》 根据中国海关数据显示：2025年5月中国医药材及药品进口数量为3.88万吨，同比增长4%，进口金额为 43.87亿美元，同比增长1.2%，2025年5月中国医药材及药品出口数量为15万吨，同比增长12.8%，出口 金额为24.22亿美元，同比增长16.8%。 ...